Intellia Therapeutics (NTLA) News Today

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is getting attention after a wave of analyst updates, with HC Wainwright reiterating a Buy rating and a $25 price target. The research note was broadly supportive, and several of the firm’s earnings estimates for 2026-2027 were revised higher, which can be seen as a positive signal for investors.

• Positive Sentiment: HC Wainwright maintained a Buy rating on Intellia Therapeutics and reaffirmed a $25 price objective, signaling continued upside confidence. Intellia Therapeutics Price Target Cut to $25.00 by Analysts at HC Wainwright
• Positive Sentiment: The firm raised its FY2026 EPS estimate to a loss of $3.00 per share from a larger loss previously expected, suggesting some improvement in the earnings outlook. Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
• Positive Sentiment: HC Wainwright also lifted near-term estimates for Q2 2026 and Q3 2026, indicating analysts now expect slightly better operating performance than before. Intellia Therapeutics, Inc. First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
• Neutral Sentiment: Other brokerage notes from Wells Fargo and Wedbush reportedly remained at Hold, suggesting the stock still has mixed analyst support.

Overall, NTLA appears to be moving on analyst optimism around its earnings trajectory rather than a company-specific operational surprise. The stock has been higher as investors weigh the improved forecasts against the fact that Intellia is still expected to post losses over the next several years.